• 1
    Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with Bacillus Calmette-Guérin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 1991; 325: 12059.
  • 2
    van der Meijden AP, Brausi M, Zambon V et al. Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J. Urol. 2001; 166: 47681.
  • 3
    Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2002; 168: 196470.
  • 4
    Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 2008; 54: 30314.
  • 5
    Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 2007; 178: 231430.
  • 6
    Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 2000; 163: 11249.
  • 7
    Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63: 6826.
  • 8
    Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 1993; 85: 36576.
  • 9
    Japanese Urological Association and the Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Bladder Cancer, 3rd edn. Kanehara Shuppan, Tokyo, 2001.
  • 10
    Akaza H, Hinotsu S, Aso Y et al. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. Cancer 1995; 75: 5529.
  • 11
    Koga H, Kuroda M, Kudo S et al. Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder. Int. J. Urol. 2005; 12: 14551.
  • 12
    Decobert M, LaRue H, Harel F et al. Maintenance Bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer. How much is enough? Cancer 2008; 113: 71016.
  • 13
    van der Meijden APM, Sylvester RJ, Oosterlinck W et al. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur. Urol. 2003; 44: 42934.